Drugs / Debio 1562M
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06969430 | May 2025 → Nov 2031 expected | acute myeloid leukemia | Debiopharm International SA | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Debio 1562M | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06969430 ↗ |
| Route | Intravenous | “Administered as intravenous (IV) infusion” NCT06969430 ↗ |